Wealth of pharmacist is up on rising shares of listed Glenmark Pharmaceuticals, which he controls with family. A new drug being developed by the firm's Swiss research unit to treat autoimmune disorders recently entered Phase II clinical trials. The firm, which derives two-thirds of its $1 billion revenues from overseas, is planning to step up its presence in the domestic market with a slew of new launches.